The purpose of the study is to determine which of the two therapies works better at controlling the disease. Participants will be randomly assigned to receive one of the two treatments, followed by regular check‑ups that may include scans such as positron emission tomography-computed tomography to look for any remaining cancer and assessments of overall health and quality of life. The study continues for several months after treatment to monitor how well the disease is controlled and to record any side effects.

Participants in the study will be randomly assigned to receive either the combination of savolitinib and osimertinib or the chemotherapy treatment. The study will monitor the participants over a period to see how the cancer responds to the treatments. The researchers will look at how long the participants live without the cancer getting worse, which is known as progression-free survival. They will also assess overall survival, which is the length of time participants live after starting the study. The study will also evaluate the safety and side effects of the treatments, as well as how the treatments affect symptoms like shortness of breath, cough, and chest pain.

This trial is open-label, meaning both the participants and the researchers know which treatment is being given. The study will continue until 2027, and it aims to provide valuable information on the best treatment options for patients with advanced or metastatic NSCLC who have specific genetic changes and have progressed after previous treatment with osimertinib.

After a stroke is diagnosed, eligible individuals receive a single infusion of the assigned treatment shortly after the event. They remain in the hospital for a few days for close monitoring of any side effects and for basic health checks. Follow‑up visits are scheduled over the next three months to track recovery, including assessments of neurological function and overall health. The study collects information on any serious bleeding events, other adverse reactions, and measures of disability and functional outcome during this period.

The purpose is to find out how safe the medicines are and whether they can lower the activity of the cancer. Adults whose disease has returned after earlier therapy (relapsed) or does not respond to usual medicines (refractory) will receive the study drugs for several treatment cycles. Participants will have regular doctor visits, blood tests, and scans to watch for side effects and to see if the cancer shrinks. Terms like “biomarker‑selected” mean that a laboratory test is used to choose patients whose cancer has a specific characteristic; “dose limiting toxicity” describes side effects that stop the dose from being increased; and “overall response rate” is the percentage of patients whose cancer gets smaller or disappears.

The purpose of the study is to evaluate the effectiveness and safety of different doses of the medication in adults with moderate to severe disease. Participants are randomly assigned to receive either the medication or the placebo by injection under the skin at regular visits for about 16 weeks. Throughout the trial, researchers check the condition of the skin, the amount of pain, quality of life and any side effects, while the study is conducted in a double‑blind manner so that neither the participants nor the study staff know which treatment is being given.

The purpose of the trial is to compare the effect of adding the new drug to usual treatment versus adding a placebo. Patients receive a combination of chemotherapy that may include irinotecan, oxaliplatin, paclitaxel albumin-bound, gemcitabine, fluorouracil, and calcium folinate hydrate. The oral study medication or the placebo is taken each day, while the chemotherapy drugs are given through an IV infusion on scheduled days.

Participants are randomly assigned to one of the two groups and neither they nor the doctors know which group they are in. Treatment cycles are repeated every few weeks, with regular visits for drug administration, blood tests, and imaging scans to check the tumor. The study continues until the disease progresses, side effects require stopping treatment, or a predefined period of follow‑up is completed.

Participants in the study will receive either Selpercatinib or a combination of the other treatments. The study will monitor the progress of the disease and how the treatments affect it. The treatments will be given through different methods, such as infusion, which is a way of delivering medicine directly into the bloodstream, or oral use, which involves taking medicine by mouth. The study will take place over a period of time, and participants will be closely observed to understand the effects of the treatments.

The study is designed to provide valuable information about the potential benefits of Selpercatinib for patients with RET Fusion-Positive Non-Small Cell Lung Cancer. By comparing it with existing treatments, researchers hope to find the most effective way to manage this type of cancer. The results of this study could lead to improved treatment options for patients in the future.

The purpose of the study is to find the optimal dose of E2086 for reducing excessive daytime sleepiness in adults with narcolepsy. Participants are randomly assigned to receive either the active tablet or placebo for several weeks. Sleepiness is measured by the time it takes to fall asleep during a series of four MWT (maintenance of wakefulness tests), reported as MSL (mean sleep latency), and by a questionnaire called the ESS that asks about the chance of dozing in everyday situations. Safety monitoring includes blood pressure checks with a device that measures pressure over 24 hours (ABPM), heart rhythm recording with a 12‑lead ECG, laboratory blood tests, and a brief interview to assess suicidal thoughts using the C‑SSRS (Columbia‑Suicide Severity Rating Scale). The study includes people with both type 1 (NT1) and type 2 (NT2) forms of narcolepsy and lasts about four weeks, with regular clinic visits for assessments.

The main aim of the study is to evaluate how often the tumors shrink, known as an objective response. Participants receive the study drug in treatment cycles that repeat every few weeks, with regular visits for physical exams, blood tests, and imaging scans to check the size of the tumor and overall health.

Tumor shrinkage is classified as a complete response when the cancer disappears, a partial response when the tumor size decreases by a significant amount, or stable disease when the tumor does not grow or shrink much. Throughout the trial, doctors monitor for adverse events, which are side effects or any unwanted medical problems, and record any that are serious or lead to stopping the treatment.

Participants in the study will receive either the MK-6194 treatment or a placebo. The study will last for about a year, during which participants will have regular check-ups to monitor their progress. The main focus will be on changes in the skin condition, particularly on the face, over a 24-week period. The study will also keep track of any side effects experienced by participants.

By the end of the study, researchers hope to gather enough information to understand how well MK-6194 works in improving the skin condition and how safe it is for patients. This information could help in developing new treatments for people with non-segmental vitiligo in the future.

The purpose of the study is to assess how well Mirikizumab works in treating these diseases over an extended period. Participants in the study will receive the medication and be monitored to see how their symptoms change over time. The study will look at whether the medication helps achieve clinical remission, which means a significant reduction or disappearance of symptoms, in participants with either Ulcerative Colitis or Crohn’s Disease.

Throughout the study, participants will receive regular injections of Mirikizumab and will have follow-up visits to track their progress. The study aims to provide valuable information on the long-term use of Mirikizumab in young patients with these chronic conditions, helping to determine its potential benefits and any side effects that may occur during treatment.

The purpose of the study is to evaluate safety and find the best dose of the new medicines when used alone or in combination. Participants receive an IV infusion, which means the medicine is delivered directly into a vein, and they swallow tablets on a regular schedule. Treatment cycles are repeated every few weeks, and patients return to the clinic for regular check‑ups, blood tests, and simple examinations to watch for any side effects.

The main purpose of the study is to determine whether Enpatoran can lower skin disease activity. Participants will take the study medication daily for about 24 weeks and will attend regular clinic visits to check their skin and overall health. Skin severity will be measured with a tool called the CLASI, which gives a number based on how much of the skin is affected and how severe the rash is. Overall lupus activity may also be evaluated using the BICLA score. Safety will be monitored by recording any side effects, referred to as TEAEs. The study will finish after the 24‑week period, and the results will show whether the drug provided a meaningful improvement.

Participants will receive their assigned medicines on a regular schedule, with IV infusions given at the clinic and oral tablets taken at home. Throughout the study, doctors will perform routine checks, imaging scans, and questionnaires to monitor tumor size, side effects, and overall health. The trial continues until a predefined number of assessments are completed or until a participant stops treatment, after which follow‑up visits assess long‑term outcomes.

The purpose of the study is to compare the safety of flecainide with that of the standard anti‑arrhythmic drugs in this patient group. After a short screening period, participants will start taking the assigned medication and will have regular clinic visits for check‑ups over a minimum of one year. During the study, doctors will record any serious problems such as death, need to stop the medication because of side effects, or unexpected hospital stays for heart failure or heart attacks.

Safety will be evaluated using several heart‑related measurements. The study will look at the QTc interval, a number on an electrocardiogram (ECG) that shows how long the heart’s electrical system takes to recharge, and the QRS duration, which reflects how quickly the heart’s electrical signal spreads. Heart‑pumping ability will be checked with the left ventricular ejection fraction, and a blood test called NT-proBNP will be used to see if the heart is under stress. Major adverse cardiovascular events, often abbreviated as MACE, such as heart‑related death, non‑fatal heart attacks, or strokes, will also be tracked.

The main goal of the trial is to evaluate the long‑term safety and tolerability of the study drug in people with the condition. After an initial screening, participants receive the medication at regular intervals for an extended period, during which doctors monitor vital signs, blood tests, heart recordings, and physical examinations. Simple walking and climbing tests are performed at the start and at later visits to see how the treatment may affect mobility.

Throughout the study, blood samples are taken to measure how much of the medicine remains in the body and to check for any immune response. All observations are recorded to help determine whether the therapy is safe for continued use over time.

The purpose of the study is to assess the safety and tolerability of these treatment regimens. Participants will receive a single injection at the start and then continue receiving additional injections according to a fixed schedule over many months. Regular visits will be scheduled to check health status, and an examination of the intestine using a camera (often called an endoscopy) will be performed around week 48 to see how the lining has responded.

Throughout the trial, researchers will closely watch for any side effects that arise after treatment and will record any new health problems. The endoscopic examination will help determine whether the inner surface of the colon shows signs of healing, providing an indication of how well the medication may be working while ensuring participants remain safe.

Participants receive the drug in a stepwise manner, starting with low doses that are gradually increased to find a level that can be tolerated without serious side effects. Once a safe dose is identified, additional participants receive that dose to see whether the cancer shows signs of shrinking or slowing. Throughout the study, regular visits include physical examinations, blood tests that measure substances such as PSA (a protein that can indicate prostate cancer activity), and imaging scans that create pictures of the inside of the body. Any side effects, changes in laboratory results, or new symptoms are recorded, and the drug may be stopped if safety concerns arise.

The main aim of the study is to see whether this new regimen works better and is safe compared with the usual care for these cancers.

Participants will receive the study medicines in repeated treatment cycles, each lasting a few weeks, with regular check‑ups to monitor tumor size and overall health. Tumor changes are measured using standard imaging and a set of rules called RECIST 1.1. The study looks at how long patients live without the cancer getting worse, known as PFS, and how long patients live overall, referred to as OS. Blood tests and heart checks are done throughout to watch for side effects.

Participants in the study will take lasmiditan as needed for their migraine attacks over a 12-month period. The study will monitor how well the medication is tolerated by the participants and will track any side effects that may occur. The study will also look at how many participants stop using the medication due to any adverse effects.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how lasmiditan works in treating migraines in children. This research aims to provide valuable insights into the long-term use of lasmiditan for managing migraines in pediatric patients.

The aim of the trial is to determine whether the combination of sarilumab and a 52‑week prednisone taper works better than prednisone taper alone in achieving lasting symptom control. Participants are randomly assigned to receive one of two dose levels of the study drug (150 mg or 200 mg) every two weeks, while all continue the steroid taper for one year, and they are followed for the same period to see how they respond.

Throughout the year, researchers check whether participants reach “remission,” meaning they have no significant pain or stiffness, and they record any side effects or laboratory changes. They also track how long remission lasts, whether symptoms return (a “flare”), and how the condition affects physical and mental well‑being using standard questionnaires. Safety is monitored continuously, and any serious problems are reported promptly.

Participants will be randomly assigned to receive either the active medication or the placebo for about one year, with regular clinic visits for injections and health checks. Blood samples will be taken to monitor liver enzymes (ALT and AST), a blood test called the ELF score that estimates liver scarring, and other measures such as cholesterol, blood sugar control (HbA1c), and body weight. Imaging tests, including a special ultrasound that measures liver stiffness (VCTE‑LSM), an MRI‑based scan (MRE), and an MRI that quantifies liver fat (MRI‑PDFF), will be performed at the start and at the end of the study to see how the liver is responding. Any side effects or abnormal lab results will be recorded throughout the study period.

The aim is to see whether the combination improves the lining of the intestine better than the injectable medication alone over a 12‑week period. Participants will receive the assigned medication(s) at regular intervals and will have routine visits where doctors may use a thin camera (a endoscopic exam) to look at the intestine and check for improvement. The study will last about three months, after which the results will be evaluated.

The goal of the trial is to find out whether adding Venetoclax to the standard three‑drug mix can improve overall survival, which means living longer after the treatment starts.

In this phase 3 study, children are placed by chance into one of two groups: one group receives the three standard drugs, and the other group receives the same three drugs plus the oral Venetoclax. Treatment is given in cycles over several weeks, and the children are checked regularly to see how they are doing and to record any side effects. The study follows each participant for a period of time to see how long they live and how they feel.

The purpose of the study is to compare the effects of Odevixibat with a placebo in children with Biliary Atresia. Participants will receive either Odevixibat or a placebo once daily. The study will last for up to 104 weeks, during which time the health of the participants will be closely monitored. The main focus will be on the time it takes for participants to require a liver transplant or experience other serious health issues related to their liver condition.

Throughout the study, various health parameters will be assessed, including liver function tests and overall health status. The study aims to provide valuable information on whether Odevixibat can help improve the outcomes for children with Biliary Atresia who have had the Kasai procedure. Participants will be regularly checked for any side effects or changes in their health to ensure their safety during the trial.

The investigational treatment is an injectable form of efimosfermin alfa, given under the skin (subcutaneous injection). Participants are randomly assigned to receive either the study drug or a placebo, and neither the participants nor the study staff know which one is given (double‑blind). The study lasts about one year, with regular clinic visits for injections and safety checks.

The main goal is to see whether the drug can improve liver health by reducing inflammation and decreasing scarring (fibrosis) compared with the placebo. Researchers will look at changes in the liver tissue, blood tests, and overall health over the treatment period.

The purpose of the trial is to compare how well the new medicine works against the standard treatment in shrinking tumors and helping patients live longer. Participants will be randomly assigned to one of the two treatment arms and will receive the assigned therapy in repeated cycles every few weeks. Throughout the study, doctors will perform regular safety checks, blood tests, and imaging scans to see how the disease responds, and they will record any side effects that occur.

Participants will take the study tablets once daily for about 12 weeks and will attend regular clinic visits where they will complete questionnaires and undergo simple tests. One questionnaire, the Epworth Sleepiness Scale, asks about the likelihood of falling asleep in everyday situations to measure daytime sleepiness. Another test, the Maintenance of Wakefulness Test, measures how long a person can stay awake while trying to stay alert. Throughout the study, researchers will monitor how the medication affects sleepiness and overall well‑being, while also checking for any side effects.

Participants in the study will be randomly assigned to receive either cabozantinib plus supportive care or just supportive care. The study will monitor the participants over a period to see how the treatment affects the progression of the disease. The trial will also assess the safety of cabozantinib and how the body processes the drug, which is known as pharmacokinetics. The study will involve regular check-ups and assessments to track the health and progress of the participants.

The trial aims to provide valuable information on whether cabozantinib can help improve the outcomes for young people with osteosarcoma. The study will last for several months, and participants will be closely monitored throughout the process to ensure their safety and to gather data on the effectiveness of the treatment. The results of this study could potentially lead to better treatment options for those affected by this challenging condition.

The purpose of the study is to understand how aspirin affects the chances of cancer coming back and the overall survival of patients with stage II and III colon cancer. Participants in the study will take either aspirin or a placebo every day for up to five years. The study is designed to be “double-blind,” meaning neither the participants nor the researchers know who is receiving aspirin and who is receiving the placebo, to ensure unbiased results.

Throughout the study, researchers will monitor the participants’ health to see if the cancer returns and to track their overall survival. The main goal is to see if taking aspirin can help improve survival rates over five years. The study will also look at how long patients remain free from cancer and how long they can continue the treatment without any issues. This research aims to provide valuable insights into the potential benefits of aspirin for patients who have undergone surgery for colon cancer.

The main aim of the trial is to assess whether the drug improves daytime alertness in participants with this condition. Volunteers will be randomly assigned to receive either the active medication or the inactive comparator, and they will take the assigned tablet each day for approximately twelve weeks. Throughout the study period, participants will attend regular visits where simple questionnaires and brief safety checks will be performed to monitor how they feel and to ensure the treatment is well tolerated.

The main goal of the trial is to see whether multiple daily doses of the medication are safe and well tolerated in healthy volunteers and to gather early information on its pharmacokinetics, which means how the body absorbs, distributes, and removes the drug. Researchers will watch for any adverse event (side effect) and will measure the amount of drug in the blood, referred to as plasma, at several time points to understand how long the drug stays in the system, its half‑life, and how quickly it is cleared.

Participants will take the assigned capsule once each day for seven days. During this period, short clinic visits will be scheduled to collect blood samples and check for any side effects. After the final dose, additional blood draws will be done to complete the safety checks and the drug‑level measurements, after which participants will be monitored for a short follow‑up period.

In the study, participants receive one booster dose of the vaccine in the muscle. The study then follows how the body responds over the next days after the booster. Blood samples are taken during the study to check for signs of protection, and any side effects such as pain, redness, swelling, headache, fever, or tiredness are recorded. The study compares the three earlier vaccination plans to see which one gives a strong response after the booster.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

In the study, one group receives letrozole together with the usual fertility treatment, while the other group receives the usual treatment without letrozole. Treatment is given during one egg collection cycle, and any embryos made from that cycle may be transferred fresh or frozen and used later within about one year. The study then follows the pregnancy outcomes after these embryo transfers. The study also looks at related conditions such as adenomyosis, a condition in which tissue similar to the lining of the womb grows into the womb muscle.

The study is designed to see whether letrozole can improve reproductive results in this setting and to collect information on pregnancy, birth, and any problems that may happen during pregnancy. It also records pain after egg collection and quality of life around the time of embryo transfer.

The main purpose of this research is to determine if the combination of these three medications can help patients live longer compared to using docetaxel by itself. The study involves two groups of patients – one receiving all three medications, while the other group receives only docetaxel. The medications are given through different methods: tislelizumab and docetaxel are given through an intravenous infusion (into a vein), while N-803 is given as a subcutaneous injection (under the skin).

During the study, patients will receive treatment and have regular check-ups to monitor their health and how well the treatment is working. The treatment will continue as long as it appears to be helping and the side effects are manageable. Doctors will use special scanning techniques to measure if the tumors are shrinking and will track how long patients live after starting the treatment.

The purpose of the study is to compare the effectiveness of LY4005130 with placebo in adults with the disorder. Participants are randomly assigned to receive either the study drug or a dummy treatment, given by infusion over several visits during a 24‑week period. The main outcome measured is the proportion of participants who reach a 75 % improvement on the facial Vitiligo Area Scoring Index (F-VASI), a score that estimates how much of the face is repigmented. Regular check‑ins monitor safety and any changes in skin color.

The purpose of the trial is to evaluate the safety and efficacy of the new combination therapy. Over a period of about four weeks, subjects will take the study medication once daily, while other participants receive a matching placebo. Safety will be monitored through reports of any side effects, regular blood tests, standard 12‑lead ECG recordings to check heart rhythm, and measurements of Sweat chloride levels, which reflect how the disease is affecting the body.

Effectiveness will be assessed by measuring lung function using the percent predicted forced expiratory volume in one second (ppFEV1) and by having participants complete a disease‑specific questionnaire that evaluates breathing symptoms (CFQ R). The study involves several clinic visits for these tests and for overall health checks.

The standard treatment in this study includes bevacizumab, oxaliplatin, fluorouracil, and calcium folinate. INCA33890 is given by vein, and the other medicines are also given as injections or infusions into a vein. People in the study are assigned by chance to one of two groups: one group receives INCA33890 with the standard treatment, and the other group receives placebo with the standard treatment. The study is blinded, which means the treatment group is not known to the people taking part or to the study team during the study.

After treatment starts, the study team follows how the cancer responds and how long the treatment helps keep the disease under control. The study also looks at how long people live and at side effects, which are unwanted health problems caused by a treatment.

People in the study are assigned by chance to receive either orelabrutinib or placebo. The study is set up so that neither the participants nor the study doctors know which treatment is being given during the trial. Treatment is taken over time, and the study follows participants to see how their condition changes during the study period.

PPMS can affect walking, balance, hand use, and other body functions. Disability progression means a gradual increase in these problems. The study is designed to compare how often this worsening happens in the two groups.